BIOCON LTD. - 532523 - Intimation Regarding Loss Of Share Certificates
Please find enclosed the details of share certificate which has been reported as lost / misplaced.11-11-2023
11-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of Newspaper advertisements published on 11.11.2023.11-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find enclosed the presentation on Q2FY24Earnings Call conducted on 10.11.2023 and video recording w.r.t. Earnings Call.11-11-2023
BIOCON LTD. - 532523 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015
Please find attached disclosure of related party transactions pursuant to Reg 23(9) of SEBI Listing Regulations, 2015.10-11-2023
Biocon reports net profit of 172.7 crore in Q2
Revenue from operations for the quarter stood at 3,462. 3 crore10-11-2023
Q2FY24 Quarterly Result Announced for Biocon Ltd.
Biotechnology company Biocon announced Q2FY24 results: Consolidated Revenues for Q2FY24 grew 52% YoY to Rs 3,620 crore. Core EBITDA grew 35% to Rs 1,100 crore, representing healthy core operating margins of 32%. Net R&D; investments for the quarter grew by 9% to Rs 264 crore, representing 10% of revenues exSyngene. EBITDA for the quarter increased by 68% to Rs 900 crore, representing an EBITDA margin of 25% versus 22% in the same period last year. Depreciation, amortisation and interest increased by Rs 376 crore over last year. This is primarily related to the biosimilar business acquisition cost. Profit Before Tax and exceptional items stood at Rs 238 crore. Reported Net Profit for the quarter stood at Rs 126 crore vs Rs 47 crore last year. Kiran Mazumdar-Shaw, Executive Chairperson, Biocon, and Biocon Biologics, said, “Biocon reported a strong revenue growth this quarter of 52% YoY at Rs 3,620 crore led largely by a revenue rise of 97% in Biosimilars. EBITDA increased by 68% YoY to Rs 900 crore, a margin of 25%. Biocon Biologics is now driving the business in North America and most of the Emerging Markets, and integration of the acquired business in Europe and a few remaining countries is expected to be completed during the year. The Generics Business has expanded its geographic manufacturing presence with the acquisition of an oral solid dosage manufacturing facility in the U.S. Syngene expects Biomanufacturing to drive future growth which will be bolstered by the proposed acquisition of a largescale facility in Bengaluru. The three businesses are focused on their strategic goals aimed at profitable growth, going forward.” Result PDF10-11-2023
BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release10-11-2023
BIOCON LTD. - 532523 - Disclosure Under Regulation 30 Of SEBI LODR Regulations 2015
Disclosure under Regulation 30 of SEBI Listing Regulations 2015 - Change in KMPs who are authorised to determine materiality of an event or information and make necessary disclosures to the Stock Exchange.10-11-2023
BIOCON LTD. - 532523 - Board Meeting Outcome for Outcome Of Board Meeting Held On 10.11.2023
Outcome of Board meeting held on November 10, 202310-11-2023
BIOCON LTD. - 532523 - Financial Results For The Quarter And Half-Year Ended September 30, 2023
Outcome of Board Meeting and Financial Results for the quarter and half-year ended September 30, 202310-11-2023